Yttrium-90 Anditixafortide targets CXCR4 tumours with precision and efficacy
Radiotheranostics

Yttrium-90 Anditixafortide: A Breakthrough Therapeutic Agent for CXCR4-Expressing Metastasised Tumours

Yttrium-90 Anditixafortide targets CXCR4-expressing tumours, delivering therapeutic β– radiation precisely, improving treatment outcomes significantly.

Yttrium-90 Anditixafortide: A Breakthrough Therapeutic Agent for CXCR4-Expressing Metastasised Tumours Read Post »

, , ,